CN102274178A - Acetyl-isovaleryl tylosin nanoemulsion medicine and preparation method thereof - Google Patents
Acetyl-isovaleryl tylosin nanoemulsion medicine and preparation method thereof Download PDFInfo
- Publication number
- CN102274178A CN102274178A CN2011102461795A CN201110246179A CN102274178A CN 102274178 A CN102274178 A CN 102274178A CN 2011102461795 A CN2011102461795 A CN 2011102461795A CN 201110246179 A CN201110246179 A CN 201110246179A CN 102274178 A CN102274178 A CN 102274178A
- Authority
- CN
- China
- Prior art keywords
- acetylisovaleryl tylosin
- surfactant
- tylosin
- raw materials
- distilled water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses an acetyl-isovaleryl tylosin nanoemulsion medicine which is 1-100 nm in diameter size and consists of the following raw materials in mass percentage: 15.00%-36.00% of surfactant, 2.00%-20.00% of cosurfactant, 1.00%-5.00% of oil, 0.01%-2.00% of acetyl-isovaleryl tylosin and the balance of distilled water; the sum of the mass percentages of the raw materials is 100%. According to the invention, the stability of the acetyl-isovaleryl tylosin medicine is improved, the bioavailability of the acetyl-isovaleryl tylosin medicine is improved and the medicine metabolism time in a human body is delayed; and the assisted dosage is reduced, the production cost is lowered and the market prospect in the medical field is broad.
Description
Technical field
The invention belongs to field of medicaments, relate to a kind of novel form of medicine, be specifically related to acetylisovaleryl tylosin nanoemulsion medicine of a kind of transparent and stable and preparation method thereof.
Background technology
Acetylisovaleryl tylosin claims safe ten thousand rhzomorphs again; as a kind of new plough macrolide antibiotics; be by the commercial brand-new macrolide antibiotics of Britain Yi Ke animal health product company limited; by microbial transformation the 3rd of tylosin carried out acetylation and the 4th and carry out the isoamyl acidylate and obtain, have breakthrough meaning.Safe ten thousand rhzomorphs all have good active to Macrolide sensitive organism, drug resistance respiratory tract disease pathogen, overcome the deficiency of many Macrocyclolactone lactone kind medicines, characteristics such as having efficient, wide spectrum, be difficult for producing drug resistance, toxic and side effects is little become the good antibiotic of anti-clinically at present treating acute and chronic respiratory system and gi system disease.
The acetylisovaleryl tylosin clinical practice mainly is its tartrate.But this dosage form bioavailability is low, and dosage is bigger, easily produces drug resistance.Therefore, how to seek a kind of suitable dosage form and become a current urgent problem with the drug effect of bringing into play acetylisovaleryl tylosin more fully.
Summary of the invention
The objective of the invention is at prior art problems and defective, the acetylisovaleryl tylosin that a kind of dissolubility is good, drug loading is high, physical property is stable, bioavailability is high nanoemulsion medicine is provided.
The technical scheme that realizes the foregoing invention purpose is a kind of acetylisovaleryl tylosin nanoemulsion medicine, and this nano-emulsion drop diameter is made up of following raw materials by weight percentage between 1～100nm:
Surfactant 15.00%～36.00%, cosurfactant 2.00%～20.00%, oil 1.00%～5.00%, acetylisovaleryl tylosin 0.01%～2.00%, surplus is a distilled water, the mass percent sum of above-mentioned raw materials is 100%.
Described surfactant is any or several mixture among RH-40, tween 80, the EL-40.
Described cosurfactant is an ethanol, 1, any in 2-propylene glycol, glycerol, the 1,3 butylene glycol or several mixture.
Described oil is isopropyl myristate, ethyl acetate, oleic any or several mixture.
The optimum ratio of acetylisovaleryl tylosin nanoemulsion medicine of the present invention is: surfactant 20.00%～30.00%, cosurfactant 5.00%～15.00%, oil 2.00%～4.00%, acetylisovaleryl tylosin 0.10%～1.20%, surplus is a distilled water, and the mass percent sum of above-mentioned raw materials is 100%.
The optimum formula of acetylisovaleryl tylosin nanoemulsion medicine of the present invention is: surfactant 27.00%, cosurfactant 9.00%, oil 3.00%, acetylisovaleryl tylosin 1.00%, distilled water 60.00%.
Another object of the present invention provides the preparation method of acetylisovaleryl tylosin nanoemulsion medicine, and step is as follows:
(1) takes by weighing surfactant and cosurfactant by formula proportion and carry out compositely, calculate the HLB value of this system, stir;
(2) according to the HLB value of surfactant phase, select one or more oil, regulate its ratio, make the required HLB value of its emulsifying close with surfactant HLB mutually;
(3) in the rule change surfactant phase of 9:1～1:9 and the ratio of oil phase, to acetylisovaleryl tylosin that wherein adds formula proportion and adjuvant, stirring makes it whole dissolvings, fully stir at 20 ℃～25 ℃ slow adding distil waters, until the nanometer emulsion that forms clear, viscosity is little and has mobile yellow transparent.
The nano-emulsion substrate that the present invention adopts is made up of surfactant, cosurfactant, oil phase and water 4 parts, is the isotropic thermodynamic stable system of a kind of particle diameter between 10～100nm.The prescription design principle: as pharmaceutical carrier, nano-emulsion at first should meet the requirement of general pharmaceutical carrier, promptly nontoxic, non-stimulated, good medicine reason effect invariably, has excellent biological compatibility, the drug effect that does not influence principal agent and stability; Owing to the nano-emulsion self characteristics, it also has special requirement to the prescription composition in addition, medicine is had stronger solubilising power and can form the stabilized nano breast in a big way distinguish.The present invention follows this principle.
In the selection of surfactant, the present invention selects the nonionic surfactant of avirulence and good biocompatibility for use.Nonionic surfactant is more stable in solution, is not subject to the influence of strong electrolyte, inorganic salts, also is not subject to the influence of soda acid, and good with the compatibility of other surfactants, and haemolysis is less.Consider preparation technology's simplicity, be the stability of the easy formation of nano-emulsion and the nano-emulsion for preparing, the present invention selects the liquid nonionic surfactant of HLB between 10～15 for use, and is perhaps composite with the nonionic surfactant of a kind of HLB＜10.Available surfactant has any or several mixture among RH-40, tween 80, the EL-40.
The HLB value of common emulsifying agent can be found in some chemical industry handbooks, as " the chemical products handbook of chemical industry publication.Because hydrophile-lipophile balance (HLB) value of surfactant has additive properties, the available quality averaging method is obtained the HLB value of surfactant.For example, after two kinds of surfactant A, B mix, the hydrophile-lipophile balance value HLB of its mixed surfactant
ABValue is
HLB
AB=（W
A?×HLB
A+W
B?×HLB
B）/(W
A+W
B)
WA in the formula, the quality of WB-mixed surfactant A, B;
HLBA, the HLB value of HLBB-surfactant A, B.
In the selection of cosurfactant, the HLB of cosurfactant energy reconciliation statement surface-active agent, and can reduce oil water interfacial tension, nano-emulsion multiselect short chain alcohol and medium chain alcohol are cosurfactant, the cosurfactant that the present invention selects for use is an ethanol, 1, in 2-propylene glycol, glycerol, the 1,3 butylene glycol any or several mixture.
The present invention is according to when the HLB of the required surfactant of emulsifying oil phase is close with surfactant, the principle that formed emulsion is stable, and the oils and fats of selecting for use has any or several mixture in isopropyl myristate, ethyl acetate, the oleic acid.These oil are in a liquid state, do not have bad abnormal smells from the patient at normal temperatures.
The present invention detects through transmission electron microscope, and droplet diameter distribution is at 10nm～100nm, and outward appearance is a yellow transparent liquid, has good stability:
1, ageing stability
Ageing stability is meant when nanometer emulsion oral liquid is preserved under room temperature nature change condition, and outward appearance prolongs and the degree that changes in time.This acetylisovaleryl tylosin nanoemulsion medicine is transparent lastingly, does not find muddy or precipitation, illustrates that then ageing stability is good.This is an important indicator estimating nano-emulsion.
2, heat storage stability
This acetylisovaleryl tylosin nanoemulsion medicine is placed test tube, and sealing places 37 ℃ of constant water bath box to store 14 days, this liquid heat storage back appearance transparent.
3, anti-freeze-stable
With this acetylisovaleryl tylosin nanoemulsion medicine in refrigerator-4 ℃ preserve a week after.Return to room temperature.If nano-emulsion becomes solids at-4 ℃, return to room temperature, return to transparent, and place one week the back continue transparently, think that then freezing-resistance is good.
4, accelerated stability
This acetylisovaleryl tylosin nanoemulsion medicine is placed test tube, and sealing under the rotating speed of 15000r/min centrifugal 20 minutes, does not have layering, still clear.
Acetylisovaleryl tylosin nanoemulsion medicine of the present invention compared with prior art has the following advantages:
1) thermodynamic stability height.Operation is fairly simple during preparation, not phase-splitting, do not precipitate, and bin stability improves;
2) light transmission is good, and any inhomogeneities or sedimentary existence easily are found, and sensible quality improves;
3) antiseptic property improves, because decentralized photo liquid is smaller, can prevent the intrusion of antibacterial, increases the dissolubility of some effective ingredient simultaneously;
4) have good solubilization, can effectively improve the dissolubility of insoluble drug;
5) can improve the dissolubility of acetylisovaleryl tylosin, delay the regression time of acetylisovaleryl tylosin, thereby improved the bioavailability of acetylisovaleryl tylosin;
6) method technology is simple, is fit to large-scale production.
Description of drawings
Fig. 1 is this suction acetylisovaleryl tylosin nanoemulsion medicine transmission electron microscope picture.
The specific embodiment
Below further set forth the in-vitro antibacterial effect of the particle diameter and the medicine of the present invention of medicine of the present invention by testing example.
Test example 1
Medicine of the present invention carries out microscopic pattern with transmission electron microscope to be observed, result's demonstration sees that Fig. 1, Fig. 1 are acetylisovaleryl tylosin nano-emulsion transmission electron microscope photos, shows acetylisovaleryl tylosin nanometer emulsion droplet, spherical in shape and be evenly distributed, favorable dispersibility, particle diameter is all less than 100nm.
Test example 2The in-vitro antibacterial result of the test of acetylisovaleryl tylosin nanoemulsion medicine of the present invention
With acetylisovaleryl tylosin crude drug, tilmicosin, enrofloxacin is contrast, and acetylisovaleryl tylosin nano-emulsion antibacterial drug of the present invention is as described below to the antibacterial efficacy of chicken virus mycoplasma.
The visible acetylisovaleryl tylosin nano-emulsion antibacterial drug of the external test of pesticide effectiveness significantly is lower than acetylisovaleryl tylosin crude drug, tilmicosin, enrofloxacin to the MIC of chicken virus mycoplasma, and this shows that it suppresses the mycoplasma effect and is better than acetylisovaleryl tylosin crude drug, tilmicosin and enrofloxacin.The results are shown in Table 1:
Table 1 minimum inhibitory concentration (MIC) (unit: ug/ml)
Below the embodiment that provides by the inventor further set forth the preparation method of acetylisovaleryl tylosin nanoemulsion medicine of the present invention.
Embodiment 1
Determine optimal proportion by oil and surfactant, cosurfactant that calculating HLB value is selected according to the rule drafting pseudo-ternary phase diagram of 9:1～1:9.Accurately take by weighing tween 80 2.0g, propylene glycol 0.2g, isopropyl myristate 0.2g, acetylisovaleryl tylosin 0.001g, surplus is a distilled water.Under 25 ℃ of room temperature conditions, manually stir as oil phase tween 80, propylene glycol, isopropyl myristate, the abundant mix homogeneously of acetylisovaleryl tylosin, then to wherein slowly adding distilled water, the limit edged manually stirs, the system viscosity is less during beginning, increase along with the distillation water yield, it is sticky that system can become, this moment, liquid crystal state or water-in-oil type nanoemulsion may appear in system, continue to drip and constantly stir, unexpected when thinning when system, what produced this moment promptly is stable yellow transparent acetylisovaleryl tylosin nano-emulsion, and its gross weight is 10g.
Embodiment 2
RH-40 3.6g, ethanol 0.5g, propylene glycol 0.5g, ethyl acetate 0.5g, acetylisovaleryl tylosin 0.05g, distilled water 4.85g.
Embodiment 3
EL-40 1.5g, ethanol 0.3g, oleic acid 0.2g, acetylisovaleryl tylosin 0.005g, distilled water 7.995g.
Embodiment 4
Tween 80 1.0g, RH-40 1.0g, 1,3 butylene glycol 0.5g, isopropyl myristate 0.1g, acetylisovaleryl tylosin 0.01g, distilled water 7.2g.
Embodiment 5
Tween 80 3.0g, ethanol 0.6g, oleic acid 0.2g, ethyl acetate 0.2g, acetylisovaleryl tylosin 0.1g, distilled water 5.9g.
Embodiment 6
Tween 80 3.0g, ethanol 2.0g, oleic acid 0.4g, acetylisovaleryl tylosin 0.2g, distilled water 4.4g.
Embodiment 7
RH-40 2.3g, glycerol 0.4g, ethanol 0.5g, ethyl acetate 0.3g, acetylisovaleryl tylosin 0.03g, distilled water 6.47g.
Embodiment 8
Tween 80 3.0g, ethanol 1.4g, oleic acid 0.4g, acetylisovaleryl tylosin 0.07g, distilled water 5.13g.
Embodiment 9
Tween 80 3.0g, ethanol 1.5g, ethyl acetate 0.5g, acetylisovaleryl tylosin 0.12g, distilled water 4.88g.
Embodiment 10
Tween 80 2.7g, ethanol 0.9g, oleic acid 0.4g, acetylisovaleryl tylosin 0.06g, distilled water 5.94g.
Embodiment 11
Tween 80 2.9g, ethanol 0.6g, 1,3 butylene glycol 0.6g, oleic acid 0.4g, acetylisovaleryl tylosin 0.04g, distilled water 5.46g.
Embodiment 12
Tween 80 2.7g, ethanol 0.9g, ethyl acetate 0.3g, acetylisovaleryl tylosin 0.1g, distilled water 6.0g.
Claims (7)
1. an acetylisovaleryl tylosin nanoemulsion medicine is characterized in that, this nano-emulsion drop diameter is made up of following raw materials by weight percentage between 1～100nm:
Surfactant 15.00%～36.00%
Cosurfactant 2.00%～20.00%
Oil 1.00%～5.00%
Acetylisovaleryl tylosin 0.01%～2.00%
Surplus is a distilled water, and the mass percent sum of above-mentioned raw materials is 100%;
Described surfactant is any or several mixture among tween 80, RH-40, the EL-40;
Described cosurfactant is an ethanol, 1, any in 2-propylene glycol, glycerol, the 1,3 butylene glycol or several mixture;
Described oil is any or several mixture in isopropyl myristate, ethyl acetate, the oleic acid;
2.Acetylisovaleryl tylosin nanoemulsion medicine according to claim 1 is characterized in that, is made up of following raw materials by weight percentage:
Surfactant 20.00%～30.00%
Cosurfactant 5.00%～15.00%
Oil 2.00%～4.00%
Acetylisovaleryl tylosin 0.10%～1.20%
Surplus is a distilled water, and the mass percent sum of above-mentioned raw materials is 100%.
2. an acetylisovaleryl tylosin nanoemulsion medicine is characterized in that, is made up of following raw materials by weight percentage:
Surfactant 27.00%
Cosurfactant 9.00%
Oil 3.00%
Acetylisovaleryl tylosin 1.00%
Distilled water 60.00%.
3. an acetylisovaleryl tylosin nanoemulsion medicine is characterized in that, is made up of following raw materials by weight percentage:
RH-40 3.6g, ethanol 0.5g, propylene glycol 0.5g, ethyl acetate 0.5g, acetylisovaleryl tylosin 0.05g, distilled water 4.85g.
4. an acetylisovaleryl tylosin nanoemulsion medicine is characterized in that, is made up of following raw materials by weight percentage:
EL-40 1.5g, ethanol 0.3g, oleic acid 0.2g, acetylisovaleryl tylosin 0.005g, distilled water 7.995g.
5. an acetylisovaleryl tylosin nanoemulsion medicine is characterized in that, is made up of following raw materials by weight percentage:
Tween 80 3.0g, ethanol 0.6g, oleic acid 0.2g, ethyl acetate 0.2g, acetylisovaleryl tylosin 0.1g, distilled water 5.9g.
6. an acetylisovaleryl tylosin nanoemulsion medicine is characterized in that, is made up of following raw materials by weight percentage:
Tween 80 3.0g, ethanol 1.4g, oleic acid 0.4g, acetylisovaleryl tylosin 0.07g, distilled water 5.13g.
7. the preparation method of the described acetylisovaleryl tylosin nanoemulsion medicine of claim 1 is characterized in that, may further comprise the steps:
1) takes by weighing surfactant and cosurfactant by formula proportion and carry out compositely, calculate the HLB value of this system, stir;
2) according to the HLB value of surfactant, select one or more oil, transfer its ratio, make the required HLB value of its emulsifying close with surfactant HLB value mutually;
3) in the rule change surfactant phase of 9:1～1:9 and the ratio of oil phase, to the acetylisovaleryl tylosin that wherein adds formula proportion, stirring makes it whole dissolvings, fully stir at 20 ℃～25 ℃ slow adding distil waters, until the nanometer emulsion that forms clear, viscosity is little and has mobile yellow transparent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102461795A CN102274178A (en) | 2011-08-25 | 2011-08-25 | Acetyl-isovaleryl tylosin nanoemulsion medicine and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102461795A CN102274178A (en) | 2011-08-25 | 2011-08-25 | Acetyl-isovaleryl tylosin nanoemulsion medicine and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102274178A true CN102274178A (en) | 2011-12-14 |
Family
ID=45100126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102461795A Pending CN102274178A (en) | 2011-08-25 | 2011-08-25 | Acetyl-isovaleryl tylosin nanoemulsion medicine and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102274178A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103271931A (en) * | 2013-05-20 | 2013-09-04 | 广东大华农动物保健品股份有限公司 | Compound acetylisovalery tylosin tartrate pellet and preparation method thereof |
| CN103432075A (en) * | 2013-09-17 | 2013-12-11 | 张晓燕 | Desloratadine nanoemulsion and preparation method thereof |
| CN105106114A (en) * | 2015-09-10 | 2015-12-02 | 河南科技大学 | Oil-in-water type fidaxomicin nano-emulsion and preparation method thereof |
| CN107550860A (en) * | 2017-09-15 | 2018-01-09 | 成都泠汐尚品科技有限公司 | A kind of acetylisovaleryl tylosin nano-emulsion and preparation method thereof |
| CN112972383A (en) * | 2021-04-19 | 2021-06-18 | 宁夏农林科学院动物科学研究所(宁夏草畜工程技术研究中心) | Tildipirosin nanoemulsion, preparation method and application thereof in prevention and treatment of calf colibacillosis diarrhea |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1517090A (en) * | 2003-01-20 | 2004-08-04 | 王玉万 | Animal use suspensoid injection or emulsion containing antibacterial medicine |
-
2011
- 2011-08-25 CN CN2011102461795A patent/CN102274178A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1517090A (en) * | 2003-01-20 | 2004-08-04 | 王玉万 | Animal use suspensoid injection or emulsion containing antibacterial medicine |
Non-Patent Citations (3)
| Title |
|---|
| 李向辉等: "替米考星纳米乳的制备及其质量评价", 《西北农林科技大学学报(自然科学版)》, vol. 37, no. 4, 30 April 2009 (2009-04-30), pages 42 - 46 * |
| 李宏胜等: "替米考星与泰乐菌素对畜禽常见病原菌抑菌作用比较", 《动物医学进展》, vol. 27, no. 2, 31 December 2006 (2006-12-31), pages 94 - 96 * |
| 赵东峰等: "泰乐菌素及其衍生物研究进展", 《医药产业资讯》, vol. 3, no. 15, 31 May 2006 (2006-05-31), pages 46 - 48 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103271931A (en) * | 2013-05-20 | 2013-09-04 | 广东大华农动物保健品股份有限公司 | Compound acetylisovalery tylosin tartrate pellet and preparation method thereof |
| CN103271931B (en) * | 2013-05-20 | 2015-04-22 | 广东大华农动物保健品股份有限公司 | Compound acetylisovalery tylosin tartrate pellet and preparation method thereof |
| CN103432075A (en) * | 2013-09-17 | 2013-12-11 | 张晓燕 | Desloratadine nanoemulsion and preparation method thereof |
| CN105106114A (en) * | 2015-09-10 | 2015-12-02 | 河南科技大学 | Oil-in-water type fidaxomicin nano-emulsion and preparation method thereof |
| CN107550860A (en) * | 2017-09-15 | 2018-01-09 | 成都泠汐尚品科技有限公司 | A kind of acetylisovaleryl tylosin nano-emulsion and preparation method thereof |
| CN112972383A (en) * | 2021-04-19 | 2021-06-18 | 宁夏农林科学院动物科学研究所(宁夏草畜工程技术研究中心) | Tildipirosin nanoemulsion, preparation method and application thereof in prevention and treatment of calf colibacillosis diarrhea |
| CN112972383B (en) * | 2021-04-19 | 2023-01-24 | 宁夏农林科学院动物科学研究所(宁夏草畜工程技术研究中心) | Tildipirosin nanoemulsion, preparation method and application thereof in prevention and treatment of calf colibacillosis diarrhea |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8465757B2 (en) | Nanoemulsion of resveratrol-phospholipid complex and method for preparing the same and applications thereof | |
| CN101422432B (en) | Preparation method of tilmicosin nano-emulsion antibacterial drug | |
| CN102274178A (en) | Acetyl-isovaleryl tylosin nanoemulsion medicine and preparation method thereof | |
| CN1931164A (en) | Nanometer miconazole nitrate emulsion medicine and its prepn process | |
| CN106604891A (en) | Non-aqueous liquid and semi-solid formulations of amorphous calcium carbonate | |
| Jansook et al. | Amphotericin B-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): effect of drug loading and biopharmaceutical characterizations | |
| CN105147734B (en) | Antarctic krill oil nano structured lipid carrier and preparation method thereof | |
| Anbarasan et al. | Optimization of the formulation and in-vitro evaluation of capecitabine niosomes for the treatment of colon cancer | |
| CN100528148C (en) | Oil-in-water type nanometer peonol emulsion oral liquid and its preparation process | |
| CN102302449A (en) | Oil-in-water cinnamic aldehyde nano emulsion medicament | |
| CN1850070A (en) | Quercetin solid liposome nano particle preparation and its preparing method | |
| CN104352566A (en) | Oil-in-water compound chlortetracycline nanoemulsion | |
| CN1931130A (en) | Nanometer emulsion oral liquid of andrographolide and its prepn process | |
| CN102166254A (en) | Oil-in-water type spearmint oil nano emulsion and method for preparing same | |
| CN102228432A (en) | Ofloxacin nanoemulsion antibacterial medicine and preparation method thereof | |
| Ma et al. | Formulation and physicochemical and biological characterization of etoposide-loaded submicron emulsions with biosurfactant of sophorolipids | |
| CN102302448A (en) | Oil-in-water furazolidone nano emulsion antibacterial medicament and preparation method thereof | |
| CN110392567A (en) | Fat emulsion and its manufacturing method containing drug | |
| CN104306389A (en) | Lincomycin-spectinomycin compound nano-emulsion | |
| CN101972229A (en) | Preparation method of catalase solid lipid nanoparticles preparation | |
| CN101032507B (en) | Bacteria resisting medicine of erythrocin nanometer-emulsion and the preparing method | |
| CN105796529A (en) | Preparation method and applications of gambogic acid self-assembled polymer nanoparticles | |
| CN101756899A (en) | Valnemulin nano-emulsion antibacterial medicine preparation | |
| CN104352510A (en) | Nano-emulsion containing perillaldehyde, citral and nystatin and preparation method of nano-emulsion | |
| CN102166253A (en) | Oil-in-water type elsholtzia oil nano emulsion preparation and method for preparing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111214 |